Skip to main content
. 2021 Jul 20;11:687564. doi: 10.3389/fonc.2021.687564

Figure 1.

Figure 1

The survival analysis of the 20 patients with rGBM who received anlotinib and TMZ treatment. [(A) progression-free survival; (B) overall survival].